Stockscreener 앱 받기
4.56
6.94%
-0.34
전일 마감가:
$4.90
열려 있는:
$4.93
하루 거래량:
3.71M
Relative Volume:
1.03
시가총액:
$1.25B
수익:
$8.10M
순이익/손실:
$-92.72M
주가수익비율:
-12.77
EPS:
-0.3571
순현금흐름:
$-82.52M
1주 성능:
-8.43%
1개월 성능:
-21.65%
6개월 성능:
+79.53%
1년 성능:
+188.61%
1일 변동 폭
$4.485
$4.97
1주일 범위
$4.485
$5.17
52주 변동 폭
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
TSHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.56 | 1.34B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Raymond James | Strong Buy |
| 2025-07-11 | 개시 | BofA Securities | Buy |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
Trading Recap: Can PBYI generate free cash flowJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
VIX Spike: Is Taysha Gene Therapies Inc stock good for income investors2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
New Highs: Is Emerson Electric Co gaining market shareJuly 2025 Big Picture & High Conviction Investment Ideas - baoquankhu1.vn
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock - MarketBeat
Nagendran sells Taysha gene therapies (TSHA) stock for $942k By Investing.com - Investing.com Canada
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects - Insider Monkey
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
Buybacks Report: What is KIDSs TAM Total Addressable MarketIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.3%Should You Sell? - MarketBeat
Taysha Gene Therapies Advances TSHA-102 Program - MSN
Taysha Gene Therapies (TSHA) Stock Analysis: Unveiling a 114% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Is Taysha Gene Therapies Inc. stock a buy on dipsMarket Volume Report & High Conviction Investment Ideas - ulpravda.ru
Is Taysha Gene Therapies Inc. stock attractive for long term wealth buildingJuly 2025 Earnings & Detailed Earnings Play Alerts - ulpravda.ru
Is Taysha Gene Therapies Inc. stock vulnerable to regulatory risks2025 Technical Patterns & Fast Exit and Entry Strategy Plans - Улправда
Is Taysha Gene Therapies Inc. stock a bargain at current levelsJuly 2025 Summary & Verified Chart Pattern Signals - Улправда
Can Taysha Gene Therapies Inc. stock beat analyst upgradesMarket Performance Report & High Conviction Buy Zone Alerts - ulpravda.ru
Can Taysha Gene Therapies Inc. stock rebound after recent weaknessJuly 2025 PreEarnings & Smart Money Movement Alerts - Улправда
Should I hold or sell Taysha Gene Therapies Inc. stock in 2025July 2025 Action & Reliable Entry Point Alerts - Улправда
Will Taysha Gene Therapies Inc. stock benefit from green energy trendsJuly 2025 Recap & Low Risk High Win Rate Picks - ulpravda.ru
Chardan Capital Maintains Buy Rating on TSHA at $12 | TSHA Stock News - GuruFocus
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha doses first patient in pivotal Rett syndrome gene therapy trial - Investing.com Australia
Taysha doses first patient in pivotal Rett syndrome gene therapy trial By Investing.com - Investing.com South Africa
Taysha Gene Therapies (TSHA) Advances in Rett Syndrome Gene Ther - GuruFocus
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - The Manila Times
Taysha Gene Therapies, Inc.Common Stock (NQ: TSHA - FinancialContent
Wells Fargo Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Cuts Target Price to $11 - 富途牛牛
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Highlights: Can Taysha Gene Therapies Inc stock rebound after recent weaknessIPO Watch & Precise Buy Zone Tips - moha.gov.vn
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 4.8%What's Next? - MarketBeat
Breakthrough And Pullback | 3 Stocks Deserve Close Attention: AXSM, TSHA And KALV - Sahm
Taysha Gene Therapies, Inc. (TSHA)’s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+ - MSN
Rice Hall James & Associates LLC Buys New Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap UpHere's Why - MarketBeat
Taysha Gene Therapies stock hits 52-week high at $5.98 By Investing.com - Investing.com Nigeria
Taysha Gene Therapies stock hits 52-week high at $5.98 - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Does Taysha Gene Therapies Still Offer Value After a 196.8% Year to Date Surge? - Yahoo Finance
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? - Yahoo Finance
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades - Yahoo Finance
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program - Insider Monkey
Taysha Gene Therapies Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Taysha Gene Therapies Earnings Notes - Trefis
Is Taysha Gene Therapies Inc. stock recession proofQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
How analysts rate Taysha Gene Therapies Inc. stock todayBull Run & Weekly Stock Breakout Alerts - Улправда
Earnings Report: Is Taysha Gene Therapies Inc. stock recession proofWeekly Stock Analysis & Risk Controlled Stock Alerts - Улправда
Breakouts Watch: Is Taysha Gene Therapies Inc. stock recession proof2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 1-Year HighTime to Buy? - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Taysha Gene Therapies Inc 주식 (TSHA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Jan 12 '26 |
Sale |
4.71 |
200,000 |
942,000 |
1,006,439 |
4.73%
0.92%
자본화:
|
볼륨(24시간):